Physician Assistant Exam Review

  • About
  • Contact
  • Blueprint
  • Blueprint
  • Products
  • About
  • Contact
  • Daily Emails
You are here: Home / Podcasts / S2 E035 Diabetes Type 1

S2 E035 Diabetes Type 1

http://traffic.libsyn.com/physicianassistantexamreview/035_DM_type_1.mp3

Podcast: Play in new window | Download


<< Click here to get 25 Endocrinology questions straight from my book, The Final Step >>

Kit for measuring the blood glucose level and insulinDiabetes

  • Insulin
    • Produced in the pancreas by specialized cells called islet cells. They make up 1–2% of the mass of the pancreas but yes 10–15%of the blood supply to it. Islet means small island
    • Increases cellular uptake of glucose
    • A MAJOR anabolic hormone

DM Type 1

  • When the pancreas produces little or no insulin
    • 5–10% of diabetes is type 1
    • Greater than 95% diabetes type 1 is secondary to autoimmune disease affecting the islet beta cells of the pancreas.
    • Average age of diagnosis is 14 (previously known as juvenile diabetes)
    • Normal or low body weight
    • DM is the leading cause of blindness in the United States
    • DM accounts for approximately 30% of end stage renal disease in the U.S.
    • DM patients are at increased risk for atherosclerosis

Clinical Findings

  • Early Disease Symptoms
    • DM may present with mild signs of hypoglycemia
      • Urinary frequency, polyuria, and polydipsia
      • Orthostatic hypotension and dehydration.
      • Weakness
      • Fatigue
      • Nausea and vomiting
      • Weight loss
      • Blurred vision
      • Poor wound healing
      • Bacterial and fungal infections
    • Patients may present in ketoacidosis
      • Very ill appearance
      • Nausea/vomiting
      • Polyuria & polydipsia secondary to hyperosmolar state
      • Abdominal pain
      • Change in mental state all the way two stupor
      • Fruity breath
  • Late Disease Symptoms
    • Eyes
      • Diabetic Retinopathy
        • After 20 year so DM 80% of patients will have retinopathy
        • Leaky weakened blood vessels. New weak blood vessels form and create scaring.
        • Symptoms
          • Increasing number of floaters
          • Blurry vision,
          • Vision that changes sometimes from blurry to clear,
          • Blank or dark areas in your field of vision,
          • Poor night vision
          • Colors appear faded or washed out
        • Fundal exam
          • Cotton-wool spots
          • Flame hemorrhages, dot/blot hemorrhage
    • Orthostatic hypotension due to to autonomic neuropathy and low plasma volume
    • Acanthosis nigricans
    • Neuropathy
      • Loss of sensation in limbs in a stocking glove distribution.
      • 50–80% of non traumatic lower extremity amputations are secondary to DM.
    • Atonic bladder
    • Erectile dysfunction
    • Delayed gastric emptying

Labs

  • Fasting blood glucose levels of >126 mg/dL on more than one occasion is diagnostic
  • Nonfasting blood glucose of >200 mg/dL
  • If above tests are negative but symptoms persist an oral glucose tolerance can be diagnostic. Fasting patient consumes 75 g oral glucose. Two hours later glucose level > 200 mg/dL is diagnostic
  • Hemoglobin A1c – indicates sugar levels over previous 3 months and is used for monitoring glucose control. 3.8–5.7% is normal. 5.7–6.3% is considered at risk. Over 6.3% is diagnostic.
  • Patients may have glucosuria and ketonuria

Treatment

  • All type 1 diabetics require insulin replacement therapy
  • Insulin is administered subcutaneously
  • Insulin is categorized by the rate it is metabolized
    • Rapid acting insulin
      • Lispro (Humalog), aspart (Novolog)
      • Onset: 5–15 minutes
      • Peak: 1–1.5 hours
      • Effective duration: 3–4 hours
    • Short acting insulin
      • Regular (Human R), (Novolin R)
      • Onset: 30–60 minutes
      • Peak: 2 hours
      • Effective duration: 6–8 hours
      • Used before meals
    • Intermediate acting insulin
      • NPH (Neutral protamine hagedorn), insulin zinc (Lente)
      • Onset: 2–4 hours
      • Peak: Flat
      • Effective duration: about 24 hours
      • Typically two doses daily and used in conjunction with a short acting insulin – Long acting insulin
      • Extended insulin zinc (Ultralente), Insulin glargine (Lantus)
      • Onset: 30–180 minutes
      • Peak: Lantus no peak, Ultralente 10–20hrs
      • Effective duration: 20–36 hrs
  • Diet & Education
    • Management of diet is extremely important
    • Increase fiber and complex carbohydrates – Monitor carbohydrate intake
    • Patient glucose monitor
  • Patients have increased risk for cardiovascular events
    • Treat HTN aggressively
    • Manage hyperlipidemia
  • Regular visits to podiatrist for foot care secondary to neuropathy
  • Regular diabetic eye exams

 


<< Click here to get 25 Endocrinology questions straight from my book, The Final Step >>

  • Blueprint
  • Products
  • About
  • Contact
  • Daily Emails

logo Privacy Policy | Fulfillment Policy | Terms of Service | Web design by OptimWise

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}
 

Loading Comments...